{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:36:28Z","timestamp":1792427788756,"version":"4.5.0"},"reference-count":153,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Chronic airway inflammation with variable airflow obstruction is clinical asthma, and it arises from distinct molecular and pathological mechanisms called endotypes. Biomarkers allow for precise endotype characterization and have been used in clinical trials to design, monitor, and evaluate outcomes for asthma biologic therapies. This review will highlight the central and evolving role of biomarkers for past, present, and future asthma, with a focus on regulatory-approved biologic therapies and emerging biomarkers. Established biomarkers, including serum immunoglobulin E (IgE), blood eosinophils, the fraction of exhaled nitric oxide (FeNO), and serum periostin, helped elucidate the complex pathophysiology of the eosinophilic type 2 (T2) asthma endotype. Emerging biomarkers, or older biomarkers with emerging utility, include sputum inflammatory cells (eosinophils, neutrophils, interleukins), thymus and activation-regulated chemokine (TARC), plasma eotaxin-3, eosinophil peroxidase (EPX), Clara\/club cell secretory protein (CC16), and quantitative computerized tomography (QCT) imaging biomarkers (evaluating mucus plugging, air trapping, airway wall thickness, small airway remolding) and are increasingly used in clinical trials as secondary endpoints in evaluating efficacy, as well as in the clinical setting at specialized centers. The rapid advances in asthma research, due in part to biomarkers and biologic therapies, may soon standardize an end goal: symptom-free asthma remission without exacerbations.<\/jats:p>","DOI":"10.3390\/jpm15080370","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T07:45:31Z","timestamp":1755071131000},"page":"370","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Established and Emerging Asthma Biomarkers with a Focus on Biologic Trials: A Narrative Review"],"prefix":"10.3390","volume":"15","author":[{"given":"Philip F.","family":"Lavere","sequence":"first","affiliation":[{"name":"Section of Pulmonary, Critical Care, and Sleep Medicine, Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlin M.","family":"Phillips","sequence":"additional","affiliation":[{"name":"Section of Pulmonary, Critical Care, and Sleep Medicine, Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola A.","family":"Hanania","sequence":"additional","affiliation":[{"name":"Section of Pulmonary, Critical Care, and Sleep Medicine, Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5553-6182","authenticated-orcid":false,"given":"Muhammad","family":"Adrish","sequence":"additional","affiliation":[{"name":"Section of Pulmonary, Critical Care, and Sleep Medicine, Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"key":"ref_1","unstructured":"FDA-NIH Biomarker Working Group (2016). BEST (Biomarkers, EndpointS, and other Tools) Resource, Food and Drug Administration."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur. Respir. J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1900588","DOI":"10.1183\/13993003.00588-2019","article-title":"Management of severe asthma: A European Respiratory Society\/American Thoracic Society guideline","volume":"55","author":"Holguin","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_4","unstructured":"Global Initiative for Asthma (2025, June 03). 2025 GINA Main Report. Global Strategy for Asthma Management and Prevention., Available online: https:\/\/ginasthma.org\/reports\/."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s12016-018-8712-1","article-title":"Understanding Asthma Phenotypes, Endotypes, and Mechanisms of Disease","volume":"56","author":"Kuruvilla","year":"2019","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Habib, N., Pasha, M.A., and Tang, D.D. (2022). Current Understanding of Asthma Pathogenesis and Biomarkers. Cells, 11.","DOI":"10.3390\/cells11172764"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1111\/all.16242","article-title":"Therapeutic relevance of eosinophilic inflammation and airway viral interactions in severe asthma","volume":"79","author":"Rupani","year":"2024","journal-title":"Allergy"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1056\/NEJM199501193320301","article-title":"Asthma and Wheezing in the First Six Years of Life","volume":"332","author":"Martinez","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJM199912233412603","article-title":"Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group","volume":"341","author":"Milgrom","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma","volume":"108","author":"Busse","year":"2001","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1183\/09031936.01.00092101","article-title":"The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics","volume":"18","author":"Matz","year":"2001","journal-title":"Eur. Respir. J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1398-9995.2004.00772.x","article-title":"Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE","volume":"60","author":"Humbert","year":"2005","journal-title":"Allergy"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-154-9-201105030-00002","article-title":"Omalizumab in severe allergic asthma inadequately controlled with standard therapy: A randomized trial","volume":"154","author":"Hanania","year":"2011","journal-title":"Ann. Intern. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1378\/chest.125.4.1378","article-title":"Predicting Response to Omalizumab, an Anti-IgE Antibody, in Patients With Allergic Asthma","volume":"125","author":"Bousquet","year":"2004","journal-title":"Chest"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.rmed.2007.01.011","article-title":"Predicting and evaluating response to omalizumab in patients with severe allergic asthma","volume":"101","author":"Bousquet","year":"2007","journal-title":"Respir. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1164\/rccm.201208-1414OC","article-title":"Exploring the effects of omalizumab in allergic asthma: An analysis of biomarkers in the EXTRA study","volume":"187","author":"Hanania","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): A multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and Safety of Benralizumab for Patients with Severe Asthma Uncontrolled with High-Dosage Inhaled Corticosteroids and Long-Acting \u03b22-Agonists (SIROCCO): A Randomised, Multicentre, Placebo-Controlled Phase 3 Trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.chest.2016.03.032","article-title":"Reslizumab for Inadequately Controlled Asthma with Elevated Blood Eosinophil Levels","volume":"150","author":"Bjermer","year":"2016","journal-title":"Chest"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.chest.2016.03.018","article-title":"Phase 3 Study of Reslizumab in Patients with Poorly Controlled Asthma","volume":"150","author":"Corren","year":"2016","journal-title":"Chest"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in Persistent Asthma with Elevated Eosinophil Levels","volume":"368","author":"Wenzel","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S2213-2600(21)00322-2","article-title":"Long-Term Safety and Efficacy of Dupilumab in Patients with Moderate-to-Severe Asthma (TRAVERSE): An Open-Label Extension Study","volume":"10","author":"Wechsler","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2147\/JAA.S357548","article-title":"Real-World Effectiveness of Dupilumab for Patients with Severe Asthma: A Retrospective Study","volume":"15","author":"Numata","year":"2022","journal-title":"J. Asthma Allergy"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in Adults with Uncontrolled Asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma","volume":"384","author":"Corren","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S2213-2600(15)00367-7","article-title":"Blood Eosinophil Count and Prospective Annual Asthma Disease Burden: A UK Cohort Study","volume":"3","author":"Price","year":"2015","journal-title":"Lancet Respir. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1164\/rccm.201909-1813OC","article-title":"Evidence for Exacerbation-Prone Asthma and Predictive Biomarkers of Exacerbation Frequency","volume":"202","author":"Peters","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1700019","DOI":"10.1183\/13993003.00019-2017","article-title":"Clinical and Biological Characteristics of the French COBRA Cohort of Adult Subjects with Asthma","volume":"50","author":"Pretolani","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1016\/S0140-6736(00)03496-6","article-title":"Effects of an Interleukin-5 Blocking Monoclonal Antibody on Eosinophils, Airway Hyper-Responsiveness, and the Late Asthmatic Response","volume":"356","author":"Leckie","year":"2000","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1164\/rccm.200701-085OC","article-title":"A Study to Evaluate Safety and Efficacy of Mepolizumab in Patients with Moderate Persistent Asthma","volume":"176","author":"Swenson","year":"2007","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of Mepolizumab Add-on Therapy on Health-Related Quality of Life and Markers of Asthma Control in Severe Eosinophilic Asthma (MUSCA): A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre, Phase 3b Trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jaci.2018.09.033","article-title":"Assessment of the Long-Term Safety of Mepolizumab and Durability of Clinical Response in Patients with Severe Eosinophilic Asthma","volume":"143","author":"Khatri","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1016\/j.clinthera.2016.07.010","article-title":"Long-Term Efficacy and Safety of Mepolizumab in Patients with Severe Eosinophilic Asthma: A Multi-Center, Open-Label, Phase IIIb Study","volume":"38","author":"Lugogo","year":"2016","journal-title":"Clin. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/j.clinthera.2019.07.007","article-title":"Long-Term Safety and Clinical Benefit of Mepolizumab in Patients with the Most Severe Eosinophilic Asthma: The COSMEX Study","volume":"41","author":"Khurana","year":"2019","journal-title":"Clin. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2100396","DOI":"10.1183\/13993003.00396-2021","article-title":"Stopping versus Continuing Long-Term Mepolizumab Treatment in Severe Eosinophilic Asthma (COMET Study)","volume":"59","author":"Moore","year":"2022","journal-title":"Eur. Respir. J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S2213-2600(14)70201-2","article-title":"Benralizumab, an Anti-Interleukin 5 Receptor \u03b1 Monoclonal Antibody, versus Placebo for Uncontrolled Eosinophilic Asthma: A Phase 2b Randomised Dose-Ranging Study","volume":"2","author":"Castro","year":"2014","journal-title":"Lancet Respir. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an Anti-Interleukin-5 Receptor \u03b1 Monoclonal Antibody, as Add-on Treatment for Patients with Severe, Uncontrolled, Eosinophilic Asthma (CALIMA): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral Glucocorticoid\u2013Sparing Effect of Benralizumab in Severe Asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S2213-2600(17)30190-X","article-title":"Benralizumab for Patients with Mild to Moderate, Persistent Asthma (BISE): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"5","author":"Ferguson","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for Inadequately Controlled Asthma with Elevated Blood Eosinophil Counts: Results from Two Multicentre, Parallel, Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S2213-2600(18)30406-5","article-title":"Long-Term Safety and Efficacy of Benralizumab in Patients with Severe, Uncontrolled Asthma: 1-Year Results from the BORA Phase 3 Extension Trial","volume":"7","author":"Busse","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1016\/j.jaip.2021.07.058","article-title":"Integrated Safety and Efficacy among Patients Receiving Benralizumab for up to 5 Years","volume":"9","author":"Korn","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"00238-2022","DOI":"10.1183\/23120541.00238-2022","article-title":"Complete Response to Anti-Interleukin-5 Biologics in a Real-Life Setting: Results from the Nationwide Danish Severe Asthma Register","volume":"8","author":"Soendergaard","year":"2022","journal-title":"ERJ Open Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab Efficacy and Safety in Adults with Uncontrolled Persistent Asthma Despite Use of Medium-to-High-Dose Inhaled Corticosteroids plus a Long-Acting \u03b22 Agonist: A Randomised Double-Blind Placebo-Controlled Pivotal Phase 2b Dose-Ranging Trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1016\/j.jaip.2022.05.019","article-title":"Effect of Dupilumab on Blood Eosinophil Counts in Patients with Asthma, Chronic Rhinosinusitis with Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis","volume":"10","author":"Wechsler","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/all.14151","article-title":"Dual Blockade of IL-4 and IL-13 with Dupilumab, an IL-4R\u03b1 Antibody, Is Required to Broadly Inhibit Type 2 Inflammation","volume":"75","author":"Allinne","year":"2020","journal-title":"Allergy"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S2213-2600(22)00492-1","article-title":"Long-Term Safety and Efficacy of Tezepelumab in People with Severe, Uncontrolled Asthma (DESTINATION): A Randomised, Placebo-Controlled Extension Study","volume":"11","author":"Wechsler","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S2213-2600(21)00537-3","article-title":"Evaluation of the Oral Corticosteroid-Sparing Effect of Tezepelumab in Adults with Oral Corticosteroid-Dependent Asthma (SOURCE): A Randomised, Placebo-Controlled, Phase 3 Study","volume":"10","author":"Wechsler","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"ref_53","first-page":"PA3564","article-title":"ARRIVAL: A Phase 3b Study to Assess Potential for Tezepelumab to Reduce Maintenance Inhaled Therapy and Induce Remission in Patients with Severe Asthma","volume":"64","author":"Israel","year":"2024","journal-title":"Eur. Respir. Soc."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1055\/s-0042-1743290","article-title":"FeNO in Asthma","volume":"43","author":"Loewenthal","year":"2022","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jaip.2018.04.043","article-title":"Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, a Prospective Real-World Study","volume":"7","author":"Casale","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/j.jaip.2021.01.008","article-title":"The Relationship Between FeNO and Effectiveness of Mepolizumab and Benralizumab in Severe Eosinophilic Asthma","volume":"9","author":"Hearn","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.anai.2020.09.005","article-title":"Exhaled Nitric Oxide Measurements Are Not Influenced by Anti-Eosinophil Therapy in Patients with Asthma","volume":"126","author":"Ramonell","year":"2021","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S2213-2600(18)30201-7","article-title":"Effect of Tralokinumab, an Interleukin-13 Neutralising Monoclonal Antibody, on Eosinophilic Airway Inflammation in Uncontrolled Moderate-to-Severe Asthma (MESOS): A Multicentre, Double-Blind, Randomised, Placebo-Controlled Phase 2 Trial","volume":"6","author":"Russell","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2213-2600(18)30184-X","article-title":"Tralokinumab for Severe, Uncontrolled Asthma (STRATOS 1 and STRATOS 2): Two Randomised, Double-Blind, Placebo-Controlled, Phase 3 Clinical Trials","volume":"6","author":"Panettieri","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S2213-2600(16)30265-X","article-title":"Efficacy and Safety of Lebrikizumab in Patients with Uncontrolled Asthma (LAVOLTA I and LAVOLTA II): Replicate, Phase 3, Randomised, Double-Blind, Placebo-Controlled Trials","volume":"4","author":"Hanania","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.jaip.2024.02.007","article-title":"Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 Population","volume":"12","author":"Corren","year":"2024","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S2213-2600(21)00124-7","article-title":"Baseline FeNO as a Prognostic Biomarker for Subsequent Severe Asthma Exacerbations in Patients with Uncontrolled, Moderate-to-Severe Asthma Receiving Placebo in the LIBERTY ASTHMA QUEST Study: A Post-Hoc Analysis","volume":"9","author":"Busse","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.jaip.2022.11.043","article-title":"Baseline FeNO Independently Predicts the Dupilumab Response in Patients with Moderate-to-Severe Asthma","volume":"11","author":"Pavord","year":"2023","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/j.jaip.2024.03.031","article-title":"Dupilumab Reduces Exacerbations Independent of Changes in Biomarkers in Moderate-to-Severe Asthma","volume":"12","author":"Pavord","year":"2024","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2213-2600(24)00362-X","article-title":"Effect of Dupilumab on Exhaled Nitric Oxide, Mucus Plugs, and Functional Respiratory Imaging in Patients with Type 2 Asthma (VESTIGE): A Randomised, Double-Blind, Placebo-Controlled, Phase 4 Trial","volume":"13","author":"Castro","year":"2025","journal-title":"Lancet Respir. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1111\/all.15197","article-title":"Baseline Type 2 Biomarker Levels and Response to Tezepelumab in Severe Asthma","volume":"77","author":"Corren","year":"2022","journal-title":"Allergy Eur. J. Allergy Clin. Immunol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2400316","DOI":"10.1183\/13993003.00316-2024","article-title":"Clinical Response On-Treatment Clinical Remission with Tezepelumab in a Broad Population of Patients with Severe Uncontrolled Asthma: Results over 2 Years from the NAVIGATOR and DESTINATION Studies","volume":"64","author":"Wechsler","year":"2024","journal-title":"Eur. Respir. J."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1164\/rccm.9120-11ST","article-title":"An Official ATS Clinical Practice Guideline: Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications","volume":"184","author":"Dweik","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_69","unstructured":"Asthma: Diagnosis, Monitoring and Chronic Asthma Management (BTS, NICE, SIGN) (2024). Clinical Guidelines, National Institute for Health and Care Excellence."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.rmed.2018.08.005","article-title":"Disconnect of Type 2 Biomarkers in Severe Asthma; Dominated by FeNO as a Predictor of Exacerbations and Periostin as Predictor of Reduced Lung Function","volume":"143","author":"Mansur","year":"2018","journal-title":"Respir. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200903-0392OC","article-title":"T-helper Type 2\u2013driven Inflammation Defines Major Subphenotypes of Asthma","volume":"180","author":"Woodruff","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.jaci.2012.06.025","article-title":"Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients","volume":"130","author":"Jia","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1056\/NEJMoa1106469","article-title":"Lebrikizumab Treatment in Adults with Asthma","volume":"365","author":"Corren","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1136\/thoraxjnl-2014-206719","article-title":"Lebrikizumab in moderate-to-severe asthma: Pooled data from two randomised placebo-controlled studies","volume":"70","author":"Hanania","year":"2015","journal-title":"Thorax"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/j.jaip.2020.03.038","article-title":"Prospective, Single-Arm, Longitudinal Study of Biomarkers in Real-World Patients with Severe Asthma","volume":"8","author":"Buhl","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/thorax-2022-219781","article-title":"Super-responders to anti-IL-5\/anti-IL-5R are characterized by high sputum eosinophil counts at baseline","volume":"78","author":"Gerday","year":"2023","journal-title":"Thorax"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1801127","DOI":"10.1183\/13993003.01127-2018","article-title":"Exacerbations of severe asthma in patients treated with mepolizumab. Vol. 52, European Respiratory Journal","volume":"52","author":"Shrimanker","year":"2018","journal-title":"Eur. Respir. Soc."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1056\/NEJMoa0805435","article-title":"Mepolizumab for prednisone-dependent asthma with sputum eosinophilia","volume":"360","author":"Nair","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13223-019-0337-2","article-title":"Omalizumab in patients with severe asthma and persistent sputum eosinophilia","volume":"15","author":"Mukherjee","year":"2019","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S2213-2600(21)00226-5","article-title":"Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): A double-blind, randomised, placebo-controlled, phase 2 trial","volume":"9","author":"Diver","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3904\/kjim.2023.299","article-title":"New targets for type 2-low asthma","volume":"39","author":"Quoc","year":"2024","journal-title":"Korean J. Intern. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.jaci.2013.10.011","article-title":"Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis","volume":"133","author":"Moore","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1900068","DOI":"10.1183\/13993003.00068-2019","article-title":"Elevated serum IgE, oral corticosteroid dependence and IL-17\/22 expression in highly neutrophilic asthma","volume":"54","author":"Bullone","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13223-021-00548-z","article-title":"Characteristics of inflammatory phenotypes among patients with asthma: Relationships of blood count parameters with sputum cellular phenotypes","volume":"17","author":"Shi","year":"2021","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/thx.2009.126722","article-title":"Effects of steroid therapy on inflammatory cell subtypes in asthma","volume":"65","author":"Cowan","year":"2010","journal-title":"Thorax"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S2213-2600(16)30227-2","article-title":"Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: A randomised, double-blind, placebo-controlled trial","volume":"4","author":"Metev","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.pupt.2017.05.012","article-title":"Effects of the CXCR2 antagonist AZD5069 on lung neutrophil recruitment in asthma","volume":"45","author":"Watz","year":"2017","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/resp.12550","article-title":"Association between peripheral airway function and neutrophilic inflammation in asthma","volume":"20","author":"Farah","year":"2015","journal-title":"Respirology"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"108151","DOI":"10.1016\/j.rmed.2025.108151","article-title":"High local type-2 inflammation is linked to response in severe asthma treated with anti-Interleukin-5 receptor","volume":"243","author":"Moermans","year":"2025","journal-title":"Respir. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13223-015-0081-1","article-title":"Therapeutic potential of anti-IL-6 therapies for granulocytic airway inflammation in asthma","volume":"11","author":"Chu","year":"2015","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1056\/NEJMoa050580","article-title":"Evidence of a Role of Tumor Necrosis Factor \u03b1 in Refractory Asthma","volume":"354","author":"Berry","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1517\/14712598.2014.859673","article-title":"Role of periostin, FENO, IL-13, lebrikzumab, other IL-13 antagonist and dual IL-4\/IL-13 antagonist in asthma","volume":"14","author":"Agrawal","year":"2014","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1111\/cea.12825","article-title":"Sputum interleukin-13 as a biomarker for the evaluation of asthma control","volume":"46","author":"Tsilogianni","year":"2016","journal-title":"Clin. Exp. Allergy"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1080\/00325481.2017.1321945","article-title":"Predictors of response to therapy with omalizumab in patients with severe allergic asthma\u2014A real life study","volume":"129","author":"Kallieri","year":"2017","journal-title":"Postgrad. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2400347","DOI":"10.1183\/13993003.00347-2024","article-title":"Association of airway inflammation and smoking status with IL-33 level in sputum of patients with asthma or COPD","volume":"64","author":"Abdo","year":"2024","journal-title":"Eur. Respir. J."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.jaci.2024.06.008","article-title":"Comorbid functional dyspepsia reflects IL-33\u2013mediated airway neuronal dysfunction in asthma","volume":"154","author":"Ito","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.2217\/imt.15.69","article-title":"Drug Evaluation Review: Dupilumab in Atopic Dermatitis","volume":"7","author":"Hamilton","year":"2015","journal-title":"Immunotherapy"},{"key":"ref_98","first-page":"165","article-title":"Eosinophilia Induced by Blocking the IL-4\/IL-13 Pathway: Potential Mechanisms and Clinical Outcomes","volume":"32","author":"Olaguibel","year":"2022","journal-title":"J. Investig. Allergy Clin. Immunol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1183\/09031936.04.00102504","article-title":"CCR4 ligands are up-regulated in the airways of atopic asthmatics after segmental allergen challenge","volume":"23","author":"Pilette","year":"2004","journal-title":"Eur. Respir. J."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1016\/j.jaip.2022.06.050","article-title":"Corticosteroid Responsiveness Following Mepolizumab in Severe Eosinophilic Asthma-A Randomized, Placebo-Controlled Crossover Trial (MAPLE)","volume":"10","author":"Yang","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/cea.13954","article-title":"Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases","volume":"51","author":"Hamilton","year":"2021","journal-title":"Clin. Exp. Allergy"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Kataoka, Y. (2025). Thymus and activation-regulated chemokine (CCL17) as a clinical biomarker in atopic dermatitis: Significance and limitations in the new treatment era. Front. Allergy, 5.","DOI":"10.3389\/falgy.2024.1473902"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.jaci.2015.02.039","article-title":"Correlation between CCL26 production by human bronchial epithelial cells and airway eosinophils: Involvement in patients with severe eosinophilic asthma","volume":"136","author":"Larose","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/all.12206","article-title":"Eosinophil peroxidase in sputum represents a unique biomarker of airway eosinophilia","volume":"68","author":"Nair","year":"2013","journal-title":"Allergy"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jaci.2024.03.023","article-title":"Utility of eosinophil peroxidase as a biomarker of eosinophilic inflammation in asthma","volume":"154","author":"Tang","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jaci.2024.07.004","article-title":"Sputum eosinophil peroxidase: Building a better biomarker for eosinophilic asthma","volume":"154","author":"Ackerman","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1164\/rccm.201611-2234OC","article-title":"Mepolizumab Attenuates Airway Eosinophil Numbers, but Not Their Functional Phenotype, in Asthma","volume":"196","author":"Kelly","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jaci.2017.06.033","article-title":"Sputum autoantibodies in patients with severe eosinophilic asthma","volume":"141","author":"Mukherjee","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1164\/rccm.201707-1323OC","article-title":"Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab","volume":"197","author":"Mukherjee","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1164\/ajrccm.159.2.9806064","article-title":"Lung Epithelium\u2013specific Proteins","volume":"159","author":"Hermans","year":"1999","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1164\/rccm.201409-1748LE","article-title":"Airway Epithelium Defects and Risks of Allergic Diseases: Multiple Associations Revealed by a Biomarker Study among Adolescents","volume":"191","author":"Bernard","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.jaci.2016.03.047","article-title":"Club cell secretory protein in serum and bronchoalveolar lavage of patients with asthma","volume":"138","author":"Guerra","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/1354750X.2017.1375559","article-title":"Club cell protein (CC16) in plasma, bronchial brushes, BAL and urine following an inhaled allergen challenge in allergic asthmatics","volume":"23","author":"Stenberg","year":"2018","journal-title":"Biomarkers"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"117417","DOI":"10.1016\/j.ecoenv.2024.117417","article-title":"CC16 alleviates PM2.5-induced lung epithelial cell injury and airway inflammation in asthmatic mice by inhibiting ferroptosis","volume":"289","author":"Wang","year":"2025","journal-title":"Ecotoxicol. Environ. Saf."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1164\/rccm.202206-1230OC","article-title":"Low CC16 mRNA Expression Levels in Bronchial Epithelial Cells Are Associated with Asthma Severity","volume":"207","author":"Li","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s12931-022-02211-6","article-title":"CC16 polymorphisms in asthma, asthma subtypes, and asthma control in adults from the Agricultural Lung Health Study","volume":"23","author":"Gribben","year":"2022","journal-title":"Respir. Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1164\/rccm.202301-0041OC","article-title":"Circulating CC16 and Asthma: A Population-based, Multicohort Study from Early Childhood through Adult Life","volume":"208","author":"Voraphani","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"107089","DOI":"10.1016\/j.rmed.2022.107089","article-title":"Association of serum CC16 levels with eosinophilic inflammation and respiratory dysfunction in severe asthma","volume":"206","author":"Goudarzi","year":"2023","journal-title":"Respir. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1080\/02770903.2025.2460549","article-title":"Computed tomography in severe asthma assessment: A systematic review","volume":"62","author":"Luzzi","year":"2025","journal-title":"J. Asthma"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1172\/JCI95693","article-title":"Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction","volume":"128","author":"Dunican","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1164\/rccm.202110-2265OC","article-title":"Mucus Plugs Persist in Asthma, and Changes in Mucus Plugs Associate with Changes in Airflow over Time","volume":"205","author":"Tang","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.chest.2019.02.403","article-title":"CT and Functional MRI to Evaluate Airway Mucus in Severe Asthma","volume":"155","author":"Svenningsen","year":"2019","journal-title":"Chest"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1159\/000530392","article-title":"Effect of Benralizumab on Mucus Plugs in Severe Eosinophilic Asthma","volume":"184","author":"Sakai","year":"2023","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"EVIDoa2300135","DOI":"10.1056\/EVIDoa2300135","article-title":"Tezepelumab and Mucus Plugs in Patients with Moderate-to-Severe Asthma","volume":"2","author":"Nordenmark","year":"2023","journal-title":"NEJM Evid."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1164\/rccm.202305-0802OC","article-title":"A Novel Air Trapping Segment Score Identifies Opposing Effects of Obesity and Eosinophilia on Air Trapping in Asthma","volume":"209","author":"Leung","year":"2024","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.jaci.2016.02.001","article-title":"Relationship between lung function and quantitative computed tomographic parameters of airway remodeling, air trapping, and emphysema in patients with asthma and chronic obstructive pulmonary disease: A single-center study","volume":"137","author":"Hartley","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/S0954-6111(98)90290-6","article-title":"Peripheral airways obstruction on high-resolution computed tomography in chronic severe asthma","volume":"92","author":"Carr","year":"1998","journal-title":"Respir. Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1378\/chest.08-0049","article-title":"A Multivariate Analysis of Risk Factors for the Air-Trapping Asthmatic Phenotype as Measured by Quantitative CT Analysis","volume":"135","author":"Busacker","year":"2009","journal-title":"Chest"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1378\/chest.07-2779","article-title":"Airway Remodeling Measured by Multidetector CT Is Increased in Severe Asthma and Correlates With Pathology","volume":"134","author":"Aysola","year":"2008","journal-title":"Chest"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"312","DOI":"10.18176\/jiaci.0265","article-title":"Severe Asthma Phenotypes Classified by Site of Airway Involvement and Remodeling via Chest CT Scan","volume":"28","author":"Kim","year":"2018","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1159\/000525846","article-title":"Effects of Benralizumab on Three-Dimensional Computed Tomography Analysis in Severe Eosinophilic Asthma","volume":"184","author":"Tsubokawa","year":"2023","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1164\/rccm.201908-1552OC","article-title":"Is Computed Tomography Airway Count Related to Asthma Severity and Airway Structure and Function?","volume":"201","author":"Eddy","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jaci.2024.10.024","article-title":"Effect of mepolizumab in airway remodeling in patients with late-onset severe asthma with an eosinophilic phenotype","volume":"155","author":"Domvri","year":"2025","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/jmri.22388","article-title":"Demonstration of the heterogeneous distribution of asthma in the lungs using CT and hyperpolarized helium-3 MRI","volume":"32","author":"Aysola","year":"2010","journal-title":"J. Magn. Reson. Imaging"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1164\/rccm.201709-1948OC","article-title":"Sputum Eosinophilia and Magnetic Resonance Imaging Ventilation Heterogeneity in Severe Asthma","volume":"197","author":"Svenningsen","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.chest.2020.04.056","article-title":"Effects of Anti-T2 Biologic Treatment on Lung Ventilation Evaluated by MRI in Adults With Prednisone-Dependent Asthma","volume":"58","author":"Svenningsen","year":"2020","journal-title":"Chest"},{"key":"ref_138","unstructured":"Global Initiative for Asthma (2025, August 05). 2019 GINA Main Report. Global Strategy for Asthma Management and Prevention., Available online: https:\/\/ginasthma.org\/wp-content\/uploads\/2019\/06\/GINA-2019-main-report-June-2019-wms.pdf."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"2100413","DOI":"10.1183\/13993003.00413-2021","article-title":"Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthma","volume":"58","author":"Kraft","year":"2021","journal-title":"Eur. Respir. J."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S2213-2600(25)00037-2","article-title":"Inflammatory and clinical risk factors for asthma attacks (ORACLE2): A patient-level meta-analysis of control groups of 22 randomised trials","volume":"13","author":"Meulmeester","year":"2025","journal-title":"Lancet Respir. Med."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S2213-2600(24)00299-6","article-title":"Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): A double-blind, double-dummy, active placebo-controlled randomised trial","volume":"13","author":"Ramakrishnan","year":"2025","journal-title":"Lancet Respir. Med."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.chest.2024.11.045","article-title":"The Role of Bronchial Biopsy in the Prediction of Response to Biologic Therapy in Severe Uncontrolled Asthma: A Prospective Study","volume":"167","author":"Iglesias","year":"2025","journal-title":"Chest"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.jaip.2020.10.033","article-title":"Variability in Blood Eosinophil Counts in Patients with Eosinophilic Asthma","volume":"9","author":"Corren","year":"2021","journal-title":"J. Allergy. Clin. Immunol. Pract."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1513\/AnnalsATS.202010-1249OC","article-title":"A Comprehensive Analysis of the Stability of Blood Eosinophil Levels","volume":"18","author":"Chipps","year":"2021","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"100547","DOI":"10.1016\/j.waojou.2021.100547","article-title":"Variability of Type 2 inflammatory markers guiding biologic therapy of severe asthma: A 5-year retrospective study from a single tertiary hospital","volume":"14","author":"Li","year":"2021","journal-title":"World Allergy Organ. J."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1164\/rccm.202502-0504ED","article-title":"The Rapidly Evolving Landscape of Asthma Therapies Is Exhilarating, Yet a Lack of Innovation in Clinical Trial Design Makes Feasibility A Real Concern","volume":"211","author":"Lugogo","year":"2025","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1164\/rccm.202409-1708OC","article-title":"Rademikibart Treatment for Moderate-to-Severe, Uncontrolled Asthma: A Phase 2B Randomized Trial","volume":"211","author":"Kerwin","year":"2025","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMoa2406673","article-title":"Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype","volume":"391","author":"Jackson","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"2401461","DOI":"10.1183\/13993003.01461-2024","article-title":"A proof-of-mechanism trial in asthma with lunsekimig, a bispecific NANOBODY molecule","volume":"65","author":"Deiteren","year":"2025","journal-title":"Eur. Respir. J."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1056\/NEJMoa2024257","article-title":"Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma","volume":"385","author":"Wechsler","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Corren, J., Reid, F., Moate, R., Jimenez, E., Sadiq, M., Williams, A., Rytelewski, M., Muthas, D., Brooks, D., and Lindqvist, E. (2024). S90\u2005FRONTIER-3: A randomized, phase 2a study to evaluate the efficacy and safety of tozorakimab (an anti-interleukin-33 monoclonal antibody) in early-onset asthma. \u2018A Tale of Two Biologics\u2019\u2013Monoclonal Antibodies in COPD and Asthma, BMJ Publishing Group Ltd. and British Thoracic Society.","DOI":"10.1136\/thorax-2024-BTSabstracts.96"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jaci.2021.03.044","article-title":"Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial","volume":"148","author":"Kelsen","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1164\/rccm.202412-2431VP","article-title":"Stop the Asthma Treatment Elevator, We Need to Get Off!","volume":"211","author":"Bush","year":"2025","journal-title":"Am. J. Respir. Crit. Care Med."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/15\/8\/370\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:26:05Z","timestamp":1760034365000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/15\/8\/370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":153,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["jpm15080370"],"URL":"https:\/\/doi.org\/10.3390\/jpm15080370","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,13]]}}}